Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Drug Discovery Today
|
September 28, 2011
Kinetic efficiency: the missing metric for enhancing compound quality?
Geoffrey A Holdgate, Adrian L Gill
Current Topics in Medicinal Chemistry
|
August 19, 2007
A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development
Adrian L Gill, Marcel Verdonk, Robert G Boyle, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 28, 2012
Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors
James S Scott, Adrian L Gill, Linda Godfrey, et al.
Cancer Research
|
May 1, 2020
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment
Elsa Quintana, Christopher J Schulze, Darienne R Myers, et al.
Nature
|
February 8, 2022
Automated iterative Csp<sup>3</sup>-C bond formation
Daniel J Blair, Sriyankari Chitti, Melanie Trobe, et al.
Journal of Medicinal Chemistry
|
January 22, 2005
Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation
Adrian L Gill, Martyn Frederickson, Anne Cleasby, et al.
Journal of Medicinal Chemistry
|
March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
James Cregg, Anne V Edwards, Stephanie Chang, et al.
Cell Chemical Biology
|
August 13, 2025
Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers
Wadie D Mahauad-Fernandez, Yu Chi Yang, Ian Lai, et al.
Nature Cell Biology
|
August 15, 2018
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
Robert J Nichols, Franziska Haderk, Carlos Stahlhut, et al.
Cancer Discovery
|
June 22, 2026
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Kyle J Seamon, Yongxian Zhuang, Yu Chi Yang, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Drug Discovery Today
|
September 28, 2011
Kinetic efficiency: the missing metric for enhancing compound quality?
Geoffrey A Holdgate, Adrian L Gill
Current Topics in Medicinal Chemistry
|
August 19, 2007
A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development
Adrian L Gill, Marcel Verdonk, Robert G Boyle, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 28, 2012
Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors
James S Scott, Adrian L Gill, Linda Godfrey, et al.
Cancer Research
|
May 1, 2020
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment
Elsa Quintana, Christopher J Schulze, Darienne R Myers, et al.
Nature
|
February 8, 2022
Automated iterative Csp<sup>3</sup>-C bond formation
Daniel J Blair, Sriyankari Chitti, Melanie Trobe, et al.
Journal of Medicinal Chemistry
|
January 22, 2005
Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation
Adrian L Gill, Martyn Frederickson, Anne Cleasby, et al.
Journal of Medicinal Chemistry
|
March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
James Cregg, Anne V Edwards, Stephanie Chang, et al.
Cell Chemical Biology
|
August 13, 2025
Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers
Wadie D Mahauad-Fernandez, Yu Chi Yang, Ian Lai, et al.
Nature Cell Biology
|
August 15, 2018
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
Robert J Nichols, Franziska Haderk, Carlos Stahlhut, et al.
Cancer Discovery
|
June 22, 2026
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Kyle J Seamon, Yongxian Zhuang, Yu Chi Yang, et al.
Page
of 3